Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
The DOI matches its Crossref record.
Abstract
Highly specific signal transduction inhibitors are being developed as anti-cancer agents against an array of molecular targets, with the promise of increased selectivity and lower toxicity than classic cytotoxic chemotherapy agents. Rapamycin and its analogues are a promising class of novel therapeutics that specifically inhibit signaling from the serine-threonine kinase, mammalian target of rapamycin (mTOR). mTOR is a key intermediary in multiple mitogenic signaling pathways and plays a central role in modulating proliferation and angiogenesis in normal tissues and neoplastic processes. Rapamycin potently inhibits T-cell proliferation, and is approved for clinical use as an immuno-suppressant following kidney transplantation. Hyperactivation of mTOR signaling has been implicated in tumorigenesis, and promising pre-clinical studies in several tumor types suggest that the anti-proliferative and anti-angiogenic properties of rapamycin may be useful in cancer therapy. These studies have led to several clinical trials evaluating the safety and efficacy of rapamycin analogs in cancer therapy. The goal of this article is to review the mechanism of action of rapamycin as an anti-cancer agent, and to review the clinical experience with rapamycin and rapamycin analogs as immunosuppressive and anti-neoplastic therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Viollet, B., Foretz, M., Guigas, B., Horman, S., Dentin, R., Bertrand, L., Hue, L., & Andreelli, F. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.108506 · Cited by 528
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Maycotte, P., & Thorburn, A. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.14627 · Cited by 393
Wilson, G. J., Wilson, J. M., & Manninen, A. H. (2008) · Nutrition & Metabolism · doi:10.1186/1743-7075-5-1 · Cited by 306
“HMB may exert its effects through an mTOR related mechanism, as this kinase is critical for lymphocyte proliferation [127].”
BackgroundCancer in the Transplant Recipient
Chapman, J. R., Webster, A. C., & Wong, G. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015677 · Cited by 275
Metadata
- Authors
- Rao, R., Buckner, J., & Sarkaria, J.
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-12-01
- Volume
- 4
- Issue
- 8
- Pages
- 621-635
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W2120577072
- Cited by
- 90
- References
- 0
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents. https://app.cochat.ai/papers/10.2174/1568009043332718
- The paper
- Rao, R., Buckner, J., & Sarkaria, J. (2004). Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents. Current Cancer Drug Targets. https://doi.org/10.2174/1568009043332718
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.